Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a United Kingdom-based biotechnology company. The firm is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The firm's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. The company also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Follow-Up Questions
Who is the CEO of Silence Therapeutics PLC?
Mr. Craig Tooman is the President of Silence Therapeutics PLC, joining the firm since 2021.
What is the price performance of SLN stock?
The current price of SLN is $5.03, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Silence Therapeutics PLC?
Silence Therapeutics PLC belongs to Biotechnology industry and the sector is Health Care
What is Silence Therapeutics PLC market cap?
Silence Therapeutics PLC's current market cap is $237.5M
